Brain Targeting Delivery Facilitated by Ligand-Functionalized Layered Double Hydroxide Nanoparticles

A delivery platform with highly selective permeability through the blood-brain barrier (BBB) is essential for brain disease treatment. In this research, we designed and prepared a novel target nanoplatform, that is, layered double hydroxide (LDH) nanoparticle conjugated with targeting peptide-ligand...

Full description

Saved in:
Bibliographic Details
Published in:ACS applied materials & interfaces Vol. 10; no. 24; p. 20326
Main Authors: Chen, Weiyu, Zuo, Huali, Zhang, Enqi, Li, Li, Henrich-Noack, Petra, Cooper, Helen, Qian, Yujin, Xu, Zhi Ping
Format: Journal Article
Language:English
Published: United States 20.06.2018
Subjects:
Animals
Blood-Brain Barrier
Brain
Hydroxides
Ligands
Mice
Nanoparticles
Rats
blood−brain barrier
blood-retina targeting
layered double hydroxide
bovine serum albumin coating
brain target peptide
ISSN:1944-8252, 1944-8252
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A delivery platform with highly selective permeability through the blood-brain barrier (BBB) is essential for brain disease treatment. In this research, we designed and prepared a novel target nanoplatform, that is, layered double hydroxide (LDH) nanoparticle conjugated with targeting peptide-ligand Angiopep-2 (Ang2) or rabies virus glycoprotein (RVG) via intermatrix bovine serum albumin for brain targeting. In vitro studies show that functionalization with the target ligand significantly increases the delivery efficiency of LDH nanoparticles to the brain endothelial (bEnd.3) cells and the transcytosis through the simulated BBB model, that is, bEnd.3 cell-constructed multilayer membrane. In vivo confocal neuroimaging of the rat's blood-retina area dynamically demonstrates that LDH nanoparticles modified with peptide ligands have shown a prolonged retention period within the retina vessel in comparison with the pristine LDH group. Moreover, Ang2-modified LDH nanoparticles are found to more specifically accumulate in the mouse brain than the control and RVG-modified LDH nanoparticles after 2 and 48 h intravenous injection. All these findings strongly suggest that Ang2-modified LDHs can serve as an effective targeting nanoplatform for brain disease treatment.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1944-8252
1944-8252
DOI:10.1021/acsami.8b04613